Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

Fig. 3

Echocardiographic measurements in normotensive (WKY) and hypertensive rats without (SHR) and with administration of empagliflozin (EMPA). a Representative M-mode tracings for aortic root diameter (Ao), left atrial dimension (LA), and left ventricle (LV) measurements of rats in three groups (total n = 9 for WKY, n = 7 for SHR, n = 7 for EMPA). b–i Plots of echocardiographic measurement results for LA dimension, aorta diameter, end-diastole and end-systole dimensions of left ventricle (LVIDd and LVIDs), end-systole septum thickness (IVSd), LV mass, fraction shortening (FS), and ejection fraction (EF) of LV. **P < 0.01 vs WKY, ***P < 0.001 vs WKY, #P < 0.05 vs WKY

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840